Welcome to the Oncomine Blog
-
Fusion detection in precision oncology, tradeoff decisions and genomic profiling democratization - An Interview with Dr. Eric Vail
Dr. Eric Vail is Director of Molecular Pathology, Cedars-Sinai Medical Center, Los Angeles, Californ... -
How to take advantage of the Oncomine Clinical Research Grant Program
What is the Oncomine Clinical Research Grant Program? The Oncomine Clinical Research Grant is a Ther... -
Improving Patient Access to Homologous Recombination Deficiency Testing for Precision Oncology
Introduction While next-generation sequencing (NGS) has enabled molecular characterization of tumors... -
Comprehensive Genomic Profiling (CGP): Accelerating Progress in Precision oncology
Comprehensive genomic profiling (CGP) is one of the latest innovations in next-generation sequencing... -
What is Biomarker Testing and Why is it Important in Oncology?
Thermo Fisher Scientific is committed to bringing advanced molecular testing to clinicians and their... -
RET Aberrations and EGFR Exon 20 Insertions Testing in the Complex NSCLC Biomarker Landscape
In his recent OncomineWorld webinar, Dr. Fernando López-Ríos, MD, PhD (Department of Pathology, 12 d... -
Collaborating Early to Advance Precision Medicine – A Look Inside Thermo Fisher’s CDx Program with Garret Hampton
Companion diagnostic (CDx) tests are powerful tools in precision medicine and help advance more wide... -
University of Munich Evaluates the Oncomine Comprehensive Plus Assay for HRD Detection
Our OncomineWorld event in 2021 brought thousands of professionals together from around the world to... -
Case Study: High-Quality, Cost-Effective Genomic Testing and Genetic Profiling using NGS
In a recent case study interview, pathologist Federico Jauk, head of the Sequencing Laboratory at th...